1. Home
  2. ANGX vs CGEM Comparison

ANGX vs CGEM Comparison

Compare ANGX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANGX

Angel Studios Inc.

N/A

Current Price

$4.46

Market Cap

728.5M

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$13.94

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANGX
CGEM
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
728.5M
780.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ANGX
CGEM
Price
$4.46
$13.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$9.75
$30.11
AVG Volume (30 Days)
656.5K
781.2K
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$223.78
N/A
Revenue Next Year
$38.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.99
$5.68
52 Week High
$18.90
$16.74

Technical Indicators

Market Signals
Indicator
ANGX
CGEM
Relative Strength Index (RSI) 61.05 49.92
Support Level $4.00 $6.65
Resistance Level $4.63 $16.74
Average True Range (ATR) 0.32 1.00
MACD 0.10 -0.19
Stochastic Oscillator 94.24 14.24

Price Performance

Historical Comparison
ANGX
CGEM

About ANGX Angel Studios Inc.

Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: